A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
一项随机、双盲、II 期研究，评估厄洛替尼联合或不联合舒尼替尼作为转移性非小细胞肺癌 (NSCLC) 二线治疗的疗效
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdt212
Groen H J M, Socinski M A, Grossi F, Juhasz E, Gridelli C, Baas P, Butts C A, Chmielowska E, Usari T, Selaru P, Harmon C, Williams J A, Gao F, Tye L, Chao R C, Blumenschein G R Jr
